Tumor cells have decreased ability to metabolize H2O2: Implications for pharmacological ascorbate in cancer therapy
Ascorbate (AscH−) functions as a versatile reducing agent. At pharmacological doses (P-AscH−; [plasma AscH−] ≥≈20 mM), achievable through intravenous delivery, oxidation of P-AscH− can produce a high flux of H2O2 in tumors. Catalase is the major enzyme for detoxifying high concentrations of H2O2. We...
Main Authors: | Claire M. Doskey, Visarut Buranasudja, Brett A. Wagner, Justin G. Wilkes, Juan Du, Joseph J. Cullen, Garry R. Buettner |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-12-01
|
Series: | Redox Biology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2213231716302634 |
Similar Items
-
Pharmacological ascorbate and ionizing radiation (IR) increase labile iron in pancreatic cancer
by: Justin C. Moser, et al.
Published: (2014-01-01) -
The role of mitochondria in pharmacological ascorbate-induced toxicity
by: Juan Du, et al.
Published: (2022-12-01) -
Catalase Modulates the Radio-Sensitization of Pancreatic Cancer Cells by Pharmacological Ascorbate
by: Juan Du, et al.
Published: (2021-04-01) -
Stability of aqueous solutions of ascorbate for basic research and for intravenous administration
by: Brett A. Wagner, et al.
Published: (2023-12-01) -
Pharmacological Ascorbate Elicits Anti-Cancer Activities against Non-Small Cell Lung Cancer through Hydrogen-Peroxide-Induced-DNA-Damage
by: Kittipong Sanookpan, et al.
Published: (2023-09-01)